Kallikrein-12 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Kallikrein-12 (KLK12; UniProt Q9UKR0), expressed in HEK293 cells. Suited for serine protease activity assays, inhibitor profiling, and antibody validation in human sample contexts.
Expression system
HEK293
Cat. #
REC-Kallikrein12

In stock

SKU
REC-Kallikrein12
$498.00

Target Overview

Kallikrein-12 (KLK12; UniProt Q9UKR0) is a secreted serine protease belonging to the tissue kallikrein-related peptidase (KLK) family, encoded by the KLK12 gene on chromosomal locus 19q13.4 — a region that clusters with 14 other KLK family members. The full-length precursor spans 248 amino acids and is processed to an active form following removal of the signal peptide and propeptide, yielding a mature trypsin-like serine endopeptidase. This recombinant is expressed in HEK293 mammalian cells, a system that supports appropriate glycosylation and folding for secreted serine proteases, producing material with biochemical characteristics closely reflecting the native human enzyme. Researchers use this recombinant in fluorogenic or chromogenic peptide substrate cleavage assays to characterise KLK12 enzymatic activity and determine kinetic parameters (Km, kcat, kcat/Km). The purified protein is well suited to inhibitor IC50 determination, including screening of small-molecule or peptide-based serine protease inhibitors. Because KLK12 shares substrate preference and structural homology with other KLK family members, comparative activity profiling against related proteases (e.g., KLK5, KLK14) is a common experimental design. Researchers also use this recombinant as a positive control antigen in Western blot and IHC antibody validation workflows. Laboratories validating anti-KLK12 antibodies against human tissue lysates or cell-conditioned media can pair this recombinant directly with the matched Triple Point Biologics anti-Kallikrein-12 antibody (SKU: RP-Kallikrein12) to establish a defined, well-characterised reference standard. The HEK293 expression system makes this recombinant compatible with applications requiring a mammalian glycoform, distinguishing it from bacterial or yeast-expressed alternatives where post-translational modifications may differ.

Background

Kallikrein-12 is a member of the 15-gene human tissue kallikrein (KLK) family — the largest contiguous cluster of serine protease genes in the human genome. First characterised as kallikrein-like protein 5 (KLK-L5), KLK12 encodes a trypsin-like serine endopeptidase that is secreted and thought to participate in proteolytic cascades alongside other KLK family members. Expression has been documented in a range of tissues, and dysregulation of KLK family members broadly — including KLK12 — has been investigated in the context of cancer, inflammatory disease, and microbial infection. In cancer biology, KLK12 expression has been examined using transcriptomic approaches. A 2024 spatial gene expression analysis of intraductal carcinoma of the prostate (Watanabe R et al., Int J Mol Sci, 2024; PMID 38732035) included KLK12 among genes profiled in the genomic landscape of that histological entity, reflecting the broader interest in KLK locus genes as research targets in prostate pathology. Separately, an integrated single-cell and bulk RNA-seq study in colorectal cancer (Yin W et al., Sci Rep, 2025; PMID 39757274) identified KLK12 within an inflammation-related prognostic gene signature, illustrating how transcriptomic datasets are being used to prioritise KLK family members for functional follow-up. KLK12's role in host–pathogen biology has also attracted research attention. Wang Y et al. (Acta Biomater, 2024; PMID 39305944) investigated KLK12 specifically in a tuberculosis model, demonstrating that silencing kallikrein-related peptidase 12 in M2 macrophages using targeted nanoparticles altered disease-relevant cellular responses — providing evidence for KLK12 as a functionally tractable research target in infectious disease contexts. This study illustrates a use case for recombinant KLK12 as a tool for understanding protease activity in macrophage biology. The structural and substrate-specificity overlap within the KLK family means findings from related members inform KLK12 research design. For example, KLK5 has been characterised as a priming protease for betacoronavirus spike proteins (Kim H et al., Sci Signal, 2024; PMID 39163389), motivating parallel enquiry into whether other trypsin-like KLK members share related activities. Recombinant KLK12 expressed in a mammalian system enables direct comparison of substrate preferences and inhibitor sensitivity across KLK family members under controlled in vitro conditions. Taken together, published research positions KLK12 as a serine protease of interest across oncology, immunology, and infectious disease research programmes. Recombinant KLK12 from HEK293 expression provides a reproducible, mammalian-glycoform source for enzymatic, structural, and antibody validation studies.

Applications

  • Fluorogenic peptide substrate cleavage assay to measure KLK12 serine protease activity and determine kinetic parameters (Km, kcat)
  • Small-molecule or peptide inhibitor IC50 determination against recombinant KLK12
  • Comparative KLK family activity profiling — KLK12 vs. KLK5, KLK14, and related trypsin-like proteases
  • Positive control antigen for Western blot validation of anti-KLK12 antibodies in human lysate experiments (pair with RP-Kallikrein12)
  • IHC antibody validation standard — use as a defined, concentration-controlled reference for anti-KLK12 antibody titration
  • Substrate specificity mapping by mass spectrometry using recombinant KLK12 against peptide or protein substrate libraries
  • Macrophage or cell-free reconstitution assays examining KLK12-dependent proteolytic cascade activation

References

  1. Yin W et al. Integrated single-cell and bulk RNA-seq analysis identifies a prognostic signature related to inflammation in colorectal cancer. Sci Rep. 2025. doi: 10.1038/s41598-024-84998-6. PMID: 39757274.
  2. Wang Y et al. Nanoparticles target M2 macrophages to silence kallikrein-related peptidase 12 for the treatment of tuberculosis and drug-resistant tuberculosis. Acta Biomater. 2024. doi: 10.1016/j.actbio.2024.09.026. PMID: 39305944.
  3. Kim H et al. The host protease KLK5 primes and activates spike proteins to promote human betacoronavirus replication and lung inflammation. Sci Signal. 2024. doi: 10.1126/scisignal.adn3785. PMID: 39163389.
  4. Watanabe R et al. Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. Int J Mol Sci. 2024. doi: 10.3390/ijms25094818. PMID: 38732035.
  5. Beydag-Tasöz BS et al. Integrating single-cell imaging and RNA sequencing datasets links differentiation and morphogenetic dynamics of human pancreatic endocrine progenitors. Dev Cell. 2023. doi: 10.1016/j.devcel.2023.07.019. PMID: 37591246.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma; tissue

Frequently Asked Questions

What is the expected molecular weight of recombinant Kallikrein-12 on SDS-PAGE or Western blot?

The full-length KLK12 precursor (UniProt Q9UKR0) is 248 amino acids, giving a predicted unmodified MW of ~27 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation shifts the apparent MW to approximately 30–35 kDa on reducing SDS-PAGE — consistent with what is observed for the native secreted form. A diffuse or doublet band in this range is normal and reflects glycan heterogeneity, not degradation. Under non-reducing conditions, mobility is similar since KLK12 lacks inter-chain disulfides in its mature form.

What processing form is this recombinant Kallikrein-12 — zymogen or active mature enzyme?

This product is the processed, active mature form of KLK12. The signal peptide and propeptide have been removed, yielding the trypsin-like serine endopeptidase domain that begins after the conserved activation cleavage site. It is supplied as an active enzyme in solution — no additional activation step is required before use in cleavage or kinetic assays. If your experiment specifically requires the zymogen (pro-KLK12), this product is not the appropriate choice; contact us to discuss custom options.

What peptide substrates does Kallikrein-12 cleave and what sequence specificity should I design around?

KLK12 is a trypsin-like serine protease with a preference for cleavage after Arg or Lys at the P1 position. For fluorogenic activity assays, the substrate Boc-Val-Pro-Arg-AMC or the more widely used H-D-Pro-Phe-Arg-pNA (chromogenic) are reported starting points. Z-Phe-Arg-AMC is also cleaved but with lower efficiency. For kinetic parameter determination (Km, kcat/Km), Boc-Val-Pro-Arg-AMC at concentrations ranging from 25 µM to 1 mM in assay buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.01% Tween-20) is a practical substrate series.

What assay buffer conditions work best for Kallikrein-12 activity and kinetic assays?

KLK12 is active in slightly alkaline, low-ionic-strength conditions. A well-tested starting buffer is 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.01% Tween-20 at 37°C. The enzyme is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — dilute into assay buffer immediately before use to reduce glycerol carry-over below 0.5% in the reaction. Avoid EDTA, which does not inhibit this serine protease directly, but do confirm that no DTT is introduced if testing disulfide-containing inhibitors. Pre-warm enzyme to 37°C for 5 minutes before substrate addition.

What starting concentration of recombinant Kallikrein-12 should I use for an IC50 inhibitor screen?

For IC50 determination, use KLK12 at 1–5 nM in the assay well, confirmed to give a linear signal over the measurement window (typically 30–60 min). Set substrate concentration at or near the Km (empirically determined, reported in the range of 100–300 µM for Arg-AMC substrates) so that the assay is in the Michaelis–Menten linear regime and IC50 values approximate Ki. Include a serine protease inhibitor such as PMSF or aprotinin as a positive inhibition control, and a DMSO vehicle control matched to the highest solvent concentration in your compound series (keep DMSO ≤ 1%).

Can I use recombinant Kallikrein-12 as a positive control for Western blot with the matched rabbit polyclonal antibody?

Yes — this recombinant is the recommended positive control for Western blot with the matched rabbit polyclonal antibody (SKU: RP-Kallikrein12; /anti-kallikrein-12-rabbit-polyclonal-antibody). The antibody and recombinant are produced from the same lab and validated as a pair. Load 20–50 ng of recombinant KLK12 per lane alongside your cell lysate samples. Under denaturing, reducing conditions you should detect a band at approximately 30–35 kDa. This lane also confirms antibody lot-to-lot consistency and serves as a molecular weight marker for the glycosylated species in your biological samples.

How much recombinant Kallikrein-12 should I load for Western blot positive control, and what dilution of RP-Kallikrein12 antibody works?

Load 20–50 ng of this recombinant per lane for a clean, non-saturated signal. For the matched RP-Kallikrein12 rabbit polyclonal antibody, a primary antibody dilution of 1:500–1:2000 in 5% non-fat milk/TBST typically works well, though we recommend titrating on your specific membrane and blocking conditions. The recombinant band at ~30–35 kDa will be sharper than endogenous KLK12 in tissue lysates due to the defined glycosylation profile from HEK293 expression. This pairing is particularly useful for validating antibody performance before committing to IHC or tissue microarray experiments.

How should I store and handle recombinant Kallikrein-12 to preserve enzymatic activity over time?

Upon receipt, store at -20°C in the supplied single-use aliquots (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol). Avoid repeated freeze-thaw cycles — each cycle can reduce activity by 10–20% for serine proteases. For short-term use (within 1 week), the enzyme is stable at 4°C. When diluting for assays, prepare working dilutions in assay buffer immediately before use and keep on ice; do not pre-dilute and re-freeze. Under recommended storage conditions, activity is stable for 12 months from the date of receipt. Purity is >90–95% by SDS-PAGE; endotoxin is confirmed <0.1 EU/µg by LAL assay.

Validation imagery coming soon

Western blot validation figures for REC-Kallikrein12 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →